Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Moxifloxacin Hydrochloride

FDA-approved product (tablet, oral), marketed as Avelox, Avelox In Sodium Chloride 0.8% In Plastic Container, Moxeza and 3 more.

Registered studies
50+
Lab records
54
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Moxifloxacin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Eye infection
  • Infection
  • Pneumonia
  • Sinusitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA14; WHO ATC S01AE07

Repurposing investigation

Moxifloxacin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli99.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae98.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • E. coli: measured active in 1 of 1 lab record
  • K. pneumoniae: measured active in 28 of 28 lab records
  • M. tuberculosis: measured active in 24 of 25 lab records
Open Moxifloxacin Hydrochloride in ChEMBL Registered studies below
Show the 54 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.3 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Moxifloxacin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

    NCT00419783 · start 2006-08

    Registered record
    Registry ID
    NCT00419783
    Conditions
    Healthy
    Interventions
    bilastine; Bilastine; Bilastine & Ketoconazole; Moxifloxacin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-08
    Completion
    2006-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionbilastine; Bilastine; Bilastine & Ketoconazole; Moxifloxacin +1 more
    PhasePhase 1
    Registry statusCompleted

  • Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

    NCT00357604 · start 2006-07

    Registered record
    Registry ID
    NCT00357604
    Conditions
    HIV Infections
    Interventions
    Ortho Tri-Cyclen (ethinyl estradiol + norgestimate); Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2006-07
    Completion
    2006-11
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionOrtho Tri-Cyclen (ethinyl estradiol + norgestimate); Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
    PhasePhase 1
    Registry statusCompleted

  • Evaluation of Possible Effects on the QT/ QTc Interval of Rupatadine in Healthy Volunteers

    NCT00199225 · start 2005-02

    Registered record
    Registry ID
    NCT00199225
    Conditions
    Human Experimentation (Human Volunteers)
    Interventions
    Rupatadine; moxifloxacin; Continous electrocardiographic register; Pharmacokinetic profile
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2005-02
    Completion
    2005-07
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Experimentation (Human Volunteers)
    InterventionRupatadine; moxifloxacin; Continous electrocardiographic register; Pharmacokinetic profile
    PhasePhase 1
    Registry statusCompleted

  • Risk of Acute Liver Injury in Users of Antimicrobials

    NCT01434173 · start 2001-07

    Registered record
    Registry ID
    NCT01434173
    Conditions
    Drug-Induced Liver Injury
    Interventions
    Moxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2001-07
    Completion
    2009-03
    Enrolment
    1,299,056

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-Induced Liver Injury
    InterventionMoxifloxacin (Avelox, BAY12-8039); Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin
    PhaseNot recorded
    Registry statusCompleted

  • An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment

    NCT01881438 · start 2000-01

    Registered record
    Registry ID
    NCT01881438
    Conditions
    Retinal Detachment
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2000-01
    Completion
    2013-05
    Enrolment
    119,924

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinal Detachment
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted